September 24, 2008
Metabasis Therapeutics Initiates Diabetes Trial
Metabasis Therapeutics, a biopharmaceutical company, has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis's second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes. The trial is expected to enroll at least 40 patients.
A major milestone was achieved earlier in 2008 with the completion of the Phase IIa, 28-day proof-of-concept trial for MB07803, said Metabasis. This clinical trial provided promising results supporting the potential of MB07803 as an important new approach for treating patients with type 2 diabetes.
Paul Laikind, president and CEO of Metabasis, said: "The safety and efficacy results we have seen thus far with MB07803 are encouraging and support our belief that a direct inhibitor of the pathway responsible for the over-production of glucose in patients suffering with diabetes could be an important new therapeutic approach."